Optimization of co-culturing conditions for hiPS cell-derived cardiomyocytes and human mesenchymal stem cells by Haukipää, Tiia
 Tiia Haukipää 
OPTIMIZATION OF CO-CULTURING 
CONDITIONS FOR HIPS CELL-DERIVED 
CARDIOMYOCYTES AND HUMAN 
MESENCHYMAL STEM CELLS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lääketieteen ja terveysteknologian tiedekunta 
Syventävien opintojen kirjallinen työ 
Toukokuu 2019  
 2 
TIIVISTELMÄ 
Tiia Haukipää: Optimization of co-culturing conditions for hiPS cell-derived cardiomyocytes and human 
mesenchymal stem cells 
Syventävien opintojen kirjallinen työ 
Tampereen yliopisto 
Lääketieteen lisensiaatin tutkinto-ohjelma 
Toukokuu 2019 
 
 
Iskeemiset sydänsairaudet ovat yleisin kuolinsyy maailmanlaajuisesti. Lukuun ottamatta sydänsiirtoa, 
myokardiumia vaurioittaviin sairauksiin ei ole parantavaa hoitoa. Kantasoluteknologiasta etsitäänkin uusia 
hoitovaihtoehtoja. 
 
Ihmisen uudelleenohjelmoiduista pluripotenteista kantasoluista erilaistetuilla kardiomyosyyteillä (hiPSC-
kardiomyosyytit) voitaisiin tulevaisuudessa korvata menettyä sydänlihaskudosta. Ne ovat kuitenkin vielä 
epäkypsiä, häiriöherkkiä, eivätkä ne kiinnity tehokkaasti kohdekudokseen. Ihmisen mesenkymaalisilla 
kantasoluilla on lukuisia parakriinisia ja immunomoduloivia ominaisuuksia, jotka voisivat ratkaista näitä 
ongelmia. Tavoitteenamme oli kasvattaa kyseisiä soluja yhdistelmäviljelmissä ja optimoida tähän soveltuvat 
kasvatusolosuhteet. Lisäksi selvitimme yhdistelmäviljelyn vaikutuksia soluille, liittyen erityisesti 
kardiomyosyyttien maturaatioon. 
 
HiPSC-kardiomyosyyttejä viljeltiin kaksi viikkoa yhdessä mesenkymaalisten kantasolujen kanssa tai näiden 
elatusliuoksessa. HiPSC-kardiomyosyyttikontrolleja kasvatettiin yksin EB-liuoksessa sekä testiryhmissä 
käytetyssä mesenkymaalisten kantasolujen kasvatusliuoksessa. Viljelyistä otetuille mRNA-näytteille 
suoritettiin qPCR-analyysi, jonka lisäksi valomikroskooppi- ja fluoresenssikuvat analysoitiin. 
 
Tutkimuksemme osoitti, että hiPSC-kardiomyosyyttejä ja mesenkymaalisia kantasoluja voidaan viljellä 
onnistuneesti yhdessä. Mesenkymaaliset kantasolut proliferoituvat voimakkaasti, mikä tulisi huomioida 
solumäärissä. Kardiomyosyyttien morfologia, tumalukumäärät tai merkkigeeniekspressio eivät viitanneet 
tehostuneeseen kypsymiseen testiryhmissä. Toisaalta qPCR-tulokset viittasivat EB-kasvatusliuoksen 
soveltuvan paremmin kardiomyosyyttien viljelyyn. 
 
 
Avainsanat: kantasolututkimus, sydänlihasvaurio 
 
Tämän julkaisun alkuperäisyys on tarkastettu Turnitin OriginalityCheck –ohjelmalla.  
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1. INTRODUCTION 
 
 
Ischemic heart diseases remain as the leading cause of death worldwide (1). Ischemia damages 
the myocardium which is then replaced with non-contractile scar tissue. Myocardium itself has an 
insufficient regeneration capacity. Whereas majority of the postnatal cardiomyocytes are at post-
mitotic state, the presence of stem or progenitor type of cells have been witnessed. Also, non-
myocardial cells can modulate the regenerative process. (2) 
 
In extensive myocardial damage, the high-risk and otherwise problematic heart transplantation 
remains as the only option. Cell transplantation involving the use of different stem cell-based 
strategies could provide a future option. These stem cells include mesenchymal stem cells, 
endothelial progenitor cells, cardiac progenitor cells and pluripotent stem cells (3). However, 
clinical trials on stem cell therapy are still at their baby stages thus clinical applications in 
myocardial repair are still lacking. The main challenge in cell transplantation is its insufficiency. (3) 
 
Cardiomyocytes can be derived from induced pluripotent stem cells in vitro (iPSC-CMs) and 
could further be implanted into a recipient’s heart. Problematically, these cardiomyocytes still 
have an immature phenotype and insufficient integration into the heart. The use of pluripotent 
stem cells also possesses a tumorigenic risk. (3) 
 
Mesenchymal stem cells (MSCs) of different origin have been used in pre-clinical and clinical trials 
with promising results. The MSCs’ paracrine qualities are believed to assist the already existing 
endogenous factors in myocardial tissue repair and improve cardiomyocytes’ survival in ischemic 
conditions. MSCs may even have the potential to differentiate into cardiomyocytes in vivo. Hence 
MSCs could help to overcome the problems mentioned with iPSC-CMs. (3)  
 
We hypothesized that hMSCs and hiPSC-CMs are suitable for co-culturing. We also assumed that 
MSCs might improve these cardiomyocytes’ maturation. Thorough in vitro studies are required to 
evaluate the interaction and potential beneficial outcomes when combining human MSCs with 
human iPSC-CMs. At the beginning of this study no other publications of co-cultures involving 
hiPS-CMs and hMSCs were discovered. 
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2. LITERATURE REVIEW 
2.1 The role of stem cell research in cardiac injury 
 
Stem cells have proven themselves as a promising tool in tissue engineering for myocardial repair 
and therefore have been widely studied both in vitro and in vivo. Stem cells have the ability to self-
renewal and differentiation into various cell types. Pluripotent stem cells, and to some extent 
mesenchymal stem cells, have the potential to differentiate into cardiomyocytes (3). 
Mesenchymal stem cells can also stimulate reparation through paracrine signaling and may create 
other cardiac tissues in vivo as described later (3).  
 
Early clinical trials on stem cell therapy have been conducted using primarily bone marrow-derived 
MSCs (BOOST, POSEIDON) but also cardiac stem cells (SCIPIO), cardiosphere derived stem cells 
(CADUCEUS), embryonic stem cells (ESCORT), adipose tissue-derived stem cells and endothelial 
progenitor cells have been studied (3). As decreased left ventricular ejection fraction (LVEF) is 
associated with heart failure, LVEF is commonly used to assess the impact of stem cell therapy on 
cardiac function. Scar tissue formation and the amount of viable tissue are also often evaluated 
for being the underlying cause of cardiac failure and the target of stem cell therapy. 
 
The BOOST trial showed an improvement in the LVEF in patients who received BM-MSCs (4). 
Although this improvement was also present in the POSEIDON trial, it was statistically non-
significant. However, clinical improvement (improved NYHA classification, 6-minute walk test and 
MLHFQ scores) was evidenced in patients with ischemic cardiomyopathy after BM-MSC treatment. 
(5) In the ESCORT trial cardiac progenitor cells were generated from embryonic stem cells in vitro 
prior to administration. The LVEF increased by 10 % alongside with clinical improvement (from 
NYHA III to NYHA I) but this study involved only one patient. (6) The SCIPIO trial also demonstrated 
cardiac magnetic resonance results with significant increase in the LVEF accompanied by decrease 
in the infarct size in patients treated with c-kit+ cardiac stem cells (7). Consistently, MRI analysis 
revealed reduction in scarring and increase in viable cardiac tissue in the CADUCEUS trial (8). 
APOLLO, the first clinical trial with AdMSCs, demonstrated improvements in cardiac function, 
perfusion and reduction in scar formation (9). 
 
 
 6 
Despite the promising results, stem cell therapy has not progressed past early clinical trials. Main 
challenge has been the inadequate efficiency of treatment. Ineffective delivery methods and 
challenging conditions at the injured target site restrict engraftment of the cells. Additionally, the 
therapeutic potential of delivered cells varies depending on the donor and cell type itself. (3)  
It becomes evident that more in vitro trials are required to overcome these issues. 
 
2.2 Mesenchymal stem cells 
 
Mesenchymal stem cells (MSCs) are multipotent adult stem cells. Depending on the signaling 
pathway, MSCs can differentiate into various mesodermal tissues such as bone, cartilage, adipose 
tissue and muscle.  According to the International Society for Cell Therapy (ISCT) MSCs are defined 
by the following properties: adherence to plastic in standard culturing conditions, specific surface 
antigen expression and multipotent differentiation potential. MSCs express CD105, CD73 and 
CD90 while CD45, CD34, CD14 or CD11b, CD79a or CD19 and HLA-DR are absent. (10) As MSCs lack 
class 2 MHC molecules and express class 1 MHCs at intermediate levels, immune rejection is 
nearly absent (3). MSCs have several endogenous functions. They participate in wound healing 
and successful aging process but also maintain stem cell niches, especially hematopoietic niches. 
MSCs have been typically isolated from bone marrow, adipose tissue, umbilical cord blood, 
peripheral blood and the connective tissue of dermis and skeletal muscle. However, MSCs can be 
found in almost every tissue type. (11,12) 
 
Adipose tissue derived mesenchymal stem cells (AdMSC) have multiple advantages. AdMSCs are 
abundant and relatively easy to isolate, they have immunosuppressive properties and lack 
rejection especially when autologous cells are used (13). In culturing conditions, AdMSCs are 
highly proliferative and resemble fibroblasts (3). AdMSCs are also able to form cardiovascular 
structures (13).  
 
MSCs migrate effectively through chemotaxis. In vitro chemotactic factors such as insulin-like 
growth factor-1 (IGF-1), platelet-derived growth factor-AB, macrophage derived chemokine (MDC) 
and RANTES attract the MSCs. Supporting their role in endogenous repair, inflammatory cytokine 
TNF- amplifies this effect. Stromal derived factor-1 (SDF-1) and HGF seem to guide the MSCs to 
the site of injury. (12) However, it seems that different subtypes have different migration potential 
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and the cell culture itself affects the phenotype (14). Therefore, culturing conditions could also 
provide a tool to modify MSCs’ properties. 
 
2.3 hiPS cells and cardiac differentiation 
 
Pluripotent stem cells such as embryonic stem cells are able to proliferate while retaining their 
ability to differentiate into all human cell types and have therefore created countless 
opportunities for regenerative medicine (15,16). Yamanaka and his research group succeeded to 
create human induced pluripotent stem cells (iPSC) by reprogramming human adult’s fibroblasts 
(17). There are fewer ethical dilemmas concerning the use of iPS cells as there are with embryonic 
stem cells. This technology also enables the use of donor specific cells in medical treatment.  
 
Just as embryonic stem cells, iPS cells can be differentiated into cardiomyocytes (18–20). Today a 
few alternative methods are prevalent. In the spontaneous embryoid body (EB) method 
aggregation of the cells into a three-dimensional cluster containing three germ layers causes the 
differentiation process. The EB method is rather simple to execute yet the yield of cardiomyocytes 
is quite low, usually less than 10 %. Other alternative involves culturing of the cells with 
cardioinductive cells or their conditioned medium. Visceral endoderm-like cell line (END-2) 
originating from mouse P19 embryonal carcinoma cells is frequently used for these purposes. 
Lastly, the differentiation process can also be conducted by using cardiomyogenesis stimulating 
growth factors adopted from the natural cardiac differentiation signaling pathways such as BMP4, 
Activin A, bFGF and Wnt3. This so-called guided approach can be applied directly to 
undifferentiated iPS cells or after the formation of the embryoid bodies as to sustain the 
development process. The advantage with this approach is that it yields over 30 % 
cardiomyocytes. However, timing is crucial in this method as the effect of the growth factors 
depend on the step of differentiation. (20,21) 
 
2.4 hiPS-cardiomyocytes and their properties 
 
The generation of hiPS-derived cardiomyocytes (hiPS-CMs) has created several opportunities for 
regenerative medicine. The hiPS-CMs could enable the use of autologous cells in stem cell therapy. 
They have also provided information as in vitro models for monogenic cardiac diseases. Other 
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possible applications involve the use of hiPS-CMs in cardiotoxicity screening and drug 
development. (21) 
 
Even though exhibiting cardiac specific structures and biophysiological properties, the phenotype 
of hiPS-derived cardiomyocytes (hiPS-CMs) has proven rather immature. Morphologically hiPS-
CMs resemble more fetal cardiomyocytes than their adult counterparts. Adult cardiomyocytes 
appear rod-like with oriented sarcomere structures, whereas hiPS-CMs are often round or cubic in 
shape and their sarcomeres are fairly disorganized and shorter. (20,22,23) Cardiomyocytes differ 
from most cell types by being partially polynuclear. Around 20% of adult cardiomyocytes are 
multinucleated whereas less than 1 % of hiPS-CMs express this feature (20,22). In an adult heart 
different cardiac subunits such as atrial, ventricular and pacemaker cells have been organized into 
a functional structure which is yet to be achieved in vitro. (20) 
 
Also, the biophysiological properties of hiPS-CMs differ somewhat from mature cardiomyocytes. 
As mature cardiomyocytes’ metabolism relies mainly on aerobic -oxidation of fatty acids, in 
immature cells this is replaced by glycolysis (23,24). This theory is supported by the low count of 
mitochondria in immature cells (23). Although hiPS-CMs are able to contract spontaneously, their 
upstroke velocity, conduction velocity and contractile force are inferior to their adult counterparts 
(23). Although these contractions are initiated by intracellular calcium, the calcium handling in 
hiPS-CMs isn’t as developed as in adult cardiomyocytes, most likely due to immature sarcoplasmic 
reticulum (20). There are many applications to evaluate these electrophysiological functions. To 
name a few, multielectrode array (MEA) is used to measure field potentials whereas patch clamp 
mechanism detects ion currents. The contractility, on the other hand, can be estimated by video 
microscopy although the non-linear shape of the cells affect the analysis. (22) 
 
Associated with the morphology and biophysiological properties, hiPS-CMs’ expression of 
structural, junctional and regulatory proteins is typically lower or varies compared to mature 
cardiomyocytes. The presence of these proteins can be indirectly evaluated by the expression of 
the corresponding encoding genes. Cardiac sarcomeric components such as -myosin heavy chain 
(-MHC), -myosin heavy chain (-MHC), -actinin and cardiac isoform of Troponin-T (cTnT) are 
encoded by MYH6, MYH7, ACTN and TNNT2 genes, respectively. (20,24) However, these 
components can be present even at early stages of maturation. Luckily, the developing 
cardiomyocytes undergo myofibrillar isoform switching, which can be utilized to further assess the 
 9 
maturation. The relation of Troponin I indicates maturation as immature cardiomyocytes express 
slow skeletal troponin I (ssTnI/TNNI1) but only adult cardiomyocytes express cardiac troponin I 
(cTnI/TNNI3). (22) Increase in the MYH7/MYH6-ratio is also associated with cardiac maturation 
since the human heart expresses more -MHC than -MHC but there is relatively more -MHC 
present in the fetal heart (23). The expression of various proteins related to ion passaging on the 
sarcolemma and sarcoplasmic reticulum has also proven lower in hiPSC-CMs than in mature 
cardiomyocytes (23). From the regulatory perspective, hiPSC-CMs often express transcription 
factors GATA-4, Nkx2.5, Isl-1, Tbx-20 and Mef2c which again are related to cardiogenesis (20,24).  
 
Along with inadequate function of immature cells, undifferentiated cells could result in teratomas 
or non-cardiac cells (25). In vivo trials in turn have demonstrated that the retention rate of hiPSC-
CMs in the injured heart is low, most likely due to ischemic conditions (3,25). Infarcted 
myocardium is a hostile environment and the delivered cells need to endure hypoxic and 
inflammatory conditions, attach to the host tissue and survive.  
 
Various of strategies have been described to improve these cells’ survival including cell 
conditioning prior to transplant, utilization of anti-apoptotic pathways, inflammation inhibition, 
angiogenic and homing factors and co-transplantation with a supporting cell type. Cell 
conditioning can be used to induce endogenous cellular survival mechanisms while suppressing 
apoptotic pathways. It can also be used to adapt the cells to hypoxia. Angiogenesis is vital for 
reparation of damaged myocardium. Angiogenic factors can be induced during cell conditioning 
albeit pre-treating the host myocardium with angiogenic growth factors such as VEGF could also 
be utilized. Pro-inflammatory cytokines, especially interleukin-1, which are abundant in ischemic 
myocardium meditate cardiomyocyte apoptosis and fibrosis. Co-transferring cytokine inhibiting 
cells like skeletal myoblasts could therefore modulate inflammation and assist cell survival. Co-
transplantation could also facilitate implantation as it is believed to be the case with supporting 
stromal cells. (25) 
 
  
 10 
2.5 Co-culturing of MSCs and hiPSC-CMs 
2.5.1 MSCs’ properties regarding cardiac reparation 
 
Paracrine mechanisms 
MSCs are known for secreting various paracrine factors which impacts regarding cardiac repair are 
diverse. Pro-survival cytokines and growth factors such as basic fibroblast growth factor (bFGF) 
and insulin-like growth factor 1 (IGF-1) inhibit apoptosis and support proliferation, survival and 
differentiation. Fibroblast growth factor 2 (FGF-2) and vascular endothelial growth factor (VEGF) 
on the other hand are crucial for angiogenesis. Metalloproteinases remodel the extracellular 
matrix whereas hepatocyte growth factor (HGF), interleukin 6 (IL-6) and prostaglandin E2 (PGE2) 
modulate the immune system, especially by T-cell downregulation. (3,11)  
 
In vitro studies on MSCs have demonstrated they secrete growth factors IGF-1, HGF, VEGF and 
FGF-2. These factors have been upregulated in hypoxic MSCs overexpressing pro-survival gene 
Akt1 and have since improved cardiac function in rat models. In addition, akt-MSCs have produced 
frizzled related protein (Sfrp2) which supports the survival of ischemic myocardium. (11) There’s 
evidence that IGF-1 can enhance PCS-CMs’ cardiac gene expression, Ca2+ hangling and -
adrenergic response by activating Akt-kinase signaling. VEGF and FGF can also activate this 
signaling pathway. In addition, FGF increases formation of gap junctions between CMs which 
improves their electrical functions. (24) 
 
Besides soluble factors, MSCs excrete exosomes and related extracellular vesicles (EVs) that 
contain nucleic acids such as microRNAs. These microvesicles are involved in intracardiac 
communication and possess cardioprotective effects in vivo animal trials. Furthermore, hypoxia 
induces the release of EVs by the MSCs. (26) Microvesicles and soluble factors mentioned above 
have shown to enhance cardiomyocyte survival, recruit endogenous cardiac stem cells and reduce 
scarring mechanisms leading eventually to cardiac repair and functional improvements in vivo 
models. (3,11,26) 
 
We hypothesized that the paracrine factors secreted by MSCs might also support the survival of 
hiPS-cardiomyocytes and even further stimulate their maturation process via conditioned 
culturing medium. A recent study on co-culture of hiPS-cardiomyocytes and human mesenchymal 
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stem cells has shown that MSCs’ paracrine properties have supported the maturation of hiPS-
cardiomyocytes (27).  
 
Cell-to-cell contacts 
It has been demonstrated that MSCs and cardiomyocytes can also communicate through cell-to-
cell interactions (28,29). Junction formation via connexin and N-cadherin has been studied for 
their importance in electromechanical coupling (28–30). It has also been shown that MSCs are 
able to couple with cardiomyocytes through partial cell fusion and thin membrane channels, 
nanotubes. Nanotubes allow a cytosolic connection and transfer of proteins or even organelles 
between cells. These tubes and gap junctions allow the transfer of energy producing mitochondria 
from MSCs to cardiomyocytes. (28,29) An in vitro study on rat cells has shown that direct cell-to-
cell contact induces MSCs to differentiate into cardiomyocytes (31). In addition, cell-to-cell 
interaction plays a role in downregulation of NK-activity and therefore has an immunoregulatory 
aspect (26). 
 
Differentiation potential 
Although in vivo and in vitro studies on animal cells indicate that MSCs can differentiate into 
cardiomyocytes, the question whether this can be executed in fully human models remains 
controversial. Different approaches have been experimented in order to differentiate MSCs into 
cardiomyocytes: DNA methyltransferase inhibitor 5-azacytidine, modified cardiomyogenic 
medium, TSA (histone deacetylase inhibitor trichostatin A) treatment and co-culturing with 
cardiomyocytes. (11,31–33). 
 
5-azacytidine (5-aza) treatment has its limitations as repeated treatment with 5-aza prevents 
human cell growth, causes apoptosis and it has created cardiomyocyte-like cells only with animal 
cells. As for human AdMSCs, TSA treatment has increased cardiac actin mRNA expression 
significantly. The expression of cardiac myosin heavy chain, -actin, cardiac troponin I and 
connexin 43 were also increased but only direct co-culturing with rat cardiomyocytes has 
produced beating cells with gap junctions to native myocytes. (32) 
 
Other potential mechanisms for cardiomyogenesis are cytokine signaling agents such as growth 
factors and interleukins, different microenvironmental factors such as culturing medium, 
electrostatic fields and culturing substrates (34). Some studies implicate that transdifferentiation 
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requires cell-to-cell contact with native myocytes while others conflict with these findings (11,31). 
Therefore, it could be assumed that both physical and paracrine mechanisms play a role. 
 
The differentiation of mesenchymal stem cells is a complex process regulated mainly by TGF- 
superfamily, especially BMP, and Wnt signaling pathways. BMPs induce cartilage, bone, tendon 
and adipose lineages as Wnt signaling suppresses adipocyte and chondrocyte formation directing 
the differentiation process towards osteogenesis. Platelet derived growth factor (PDGF) pathway 
directs MSCs towards angiogenesis alongside with vascular endothelial growth factor (VEGF). 
Cardiogenic gene expression relies on cell-to-cell relayed transmembrane receptor Notch signaling 
pathway. (35) 
 
2.5.2 Previous studies 
 
A co-culture study on murine cells indicated that MSCs improved morphological integration of 
hiPS-CMs to nonvital and vital ventricular slices. Additionally, co-culture involving MSCs or MSC 
conditioned medium with hiPS-CMs improved electrical integration with the vital ventricular 
slices. (36) A recent study on human cells discovered that BM-MSCs improved hiPS-CMs’ 
expression of cardiac troponin T (cTnT) and other cardiac markers as well as structural, 
electrophysiological and metabolic development, motility and maturity. The maturation process 
seemed to be linked to soluble factors secreted by the MSCs but the exact mechanism remains 
unclear. (27) 
 
Due to the lack of previous research our aim is to describe the effect of hMSC and hiPS-CM co-
culture on the cells. Our additional goal is to determine the optimal medium and ratio of the cells 
in this co-culture. In an ideal situation MSCs would have beneficial effects on the cardiomyocytes 
maturation and survival without taking over the cultures. The cultures also have to be sparse 
enough for analysis and cell survival. 
 
3. MATERIALS AND METHODS 
3.1 Ethical considerations 
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The preparation and use of the iPS-cells in this study has been approved by the Ethical Committee 
of Pirkanmaa Hospital District. The donors of the skin fibroblast used to regenerate these cells 
have given their written consents for this purpose. These consents have since been filed according 
to the EU-directive regarding the use of human organs, tissues and cells in medical use.  
 
3.2 Materials 
 
The study material consists of hiPS-cell line UTA.04602.WT prepared in advance by Tampere 
University’s Heart Group. Reprogramming of the cells was performed using retroviral vectors, 
SOX-2, OCT-3/4, KLF4 and CMYC. (37) Additionally, human mesenchymal stem cells derived from 
adipose tissue (hMSC, 6/11 p.4) were used. The derivation of adipose tissue derived hMSCs have 
been described previously by Tirkkonen L et al. (38). 
 
3.3 Culturing of the hiPS cells 
 
iPS cells were cultured for 7 to 14 days in two feeder-free Geltrex™-matrix (Geltrex was diluted in 
1:100 ratio to DMEM/F-12 basal medium, Gibco Life Technologies) coated 6-well plates. mTeSR™1 
(StemCell Technologies) medium including 0,5 % Pen-Strep-antibiotic (Sigma-Aldrich) was used. 
Half of the medium was replaced every two to three days.  
 
3.4 Differentiation of the hiPS cells into cardiomyocytes 
 
The differentiation process shown in Table 1 was carried out using a method modified from the 
differentiation protocol created by Karakikes et al. (39). This method involved the spontaneous 
embryoid body formation combined with the use of growth factors. In the first batch 
approximately fourth of the targeted coverage of the wells was reached. Culturing medium was 
aspirated, and the cells dissociated by adding 1ml of versene (Thermo Fisher Scientific) per well for 
10 minutes. All the cells were resuspended in one well containing 3ml of mTeSR™1 (StemCell 
Technologies) supplemented with 5µM Blebbistatin (Sigma-Aldrich). Finally, the cells were divided 
into a 6-well low-attachment plate containing the same medium as previously. For differentiation 
the medium was changed for eleven days according to Table 1. Hence RPMI + B27 medium (Gibco, 
Life Technologies) with insulin was used and replaced every two to three days until the co-culture. 
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Table 1. The growth factor induced cardiac differentiation protocol of embryoid bodies. 
Day Medium Basal medium Growth factors 
0 mTeSR™1 mTeSR rh bFGF 
rh TGF 
Blebbistatin 
1 RPMI + B27 - 
insulin 
RPMI 5µg/ml Ascorbic acid 
10ng/ml BMP4 
25ng/ml Activin A 
3 RPMI + B27 - 
insulin 
RPMI 5µg/ml Ascorbic acid 
4 RPMI + B27 - 
insulin 
RPMI 2.5µM IWP-4 
8 RPMI + B27 - 
insulin 
RPMI - 
11 RPMI + B27 RPMI Insulin 
 
The cells were dissociated by using MACS Multi Tissue Dissociation Kit 3 (Miltenyi Biotec) 
according to the manufacturer’s instructions. After the dissociation the cells were counted by 
using a hemacytometer. In the first batch cell number was low, approximately 510 000 cells in 
total.  
 
For isolation of the cardiomyocytes MACs PSC-Derived Cardiomyocyte Isolation Kit (Miltenyi 
Biotec) and its isolation protocol was used. The first isolation yielded 163 000 cells with a purity up 
to 97 % according to Miltenyi Biotec. This amount determined the use of 4000 or 8000 hiPS-
cardiomyocytes per well depending on the desired proportion in relation to Mesenchymal stem 
cells. In a 24-well plate this resulted in a density of 2000 and 4000 cardiomyocytes/cm2. 
 
3.5 The co-culture of hiPSC-cardiomyocytes and human adipose tissue derived 
mesenchymal stem cells 
 
In total three separate batches were prepared in 24-well plates. Four different co-cultures were 
created with the percentage of mesenchymal stem cells (MSC) being 3 %, 6 %, 10 % and 20 %. 
Practically 120 MSCs were added into cultures of 2000 and 4000 cardiomyocytes which resulted in 
a ratio of 6 % and 3 % of MSCs, respectively. 10 % and 20 % well were made in the same manner 
with the MSC count being 400. In addition, hiPSC-cardiomyocytes were cultured in MSCs’ 
conditioned media and in two different control groups which contained no MSCs. The culturing 
medium used was DMEM/F12 (Thermo Fisher Scientific) with 10 % FBS (PAA Laboratories GmbH), 
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1 % glutamax (Invitrogen) and 1 % Penicillin/Streptomycin (Lonza). Half of this medium was 
replaced with MSC-culture conditioned medium for the conditioned medium samples. For the 
other control group EB medium was used and it consisted of: KO-DMEM (Thermo Fisher Scientific) 
with 20 % FBS (PAA Laboratories GmbH), 1 % non-essential aminoacids (NEAA, Cambrex Bio 
Science), 1 % glutamax and 0,5 % Penicillin/Streptomycin. In each well 1ml of medium was used, 
half of which was replaced every two to three days. 
 
The wells were plated in three different manners in order to examine the effect of the plating 
strategy. Each well was coated with Geltrex. Additionally, in the first batch the wells were covered 
with glass slips and the cardiomyocytes were plated in a droplet onto the gel. In the second batch 
glass slips weren’t used and cardiomyocytes were plated into the media. In the third batch both of 
the previous methods were used but the cardiomyocytes were also plated in a droplet without the 
slips. The different plating strategies are illustrated in the following diagram 1 which represents 
the third plate.  
 
8000 CMs 8000 CMs 4000 CMs 8000 CMs 4000 CMs 4000 CMs 
Control 
Droplet + slip 
3% MSC 
Droplet + 
slip 
6% MSC 
Droplet + 
slip 
10% MSC 
Droplet + 
slip 
20% MSC 
Droplet + 
slip 
Conditioned 
Droplet + slip 
Control 
Droplet 
3% MSC 
Droplet 
6% MSC 
Droplet 
10% MSC 
Droplet 
20% MSC 
Droplet 
Conditioned 
Droplet 
EB control 
Droplet + slip 
3% MSC 
- 
6% MSC 
- 
10% MSC 
- 
20% MSC 
- 
Conditioned 
- 
EB control 
Droplet 
3% MSC 
- 
6% MSC 
- 
10% MSC 
- 
20% MSC 
- 
Conditioned 
- 
Diagram 1. Example of the 24-well plate representing the third batch. The different MSC concentrations were  
achieved by altering the number of plated hiPSC-CMs (8000 or 4000). Control stands for MSC medium control. 
 
 
3.6 Microscopy imaging of the co-cultures 
 
The co-cultures were observed for 14 days by using Nikon Eclipse TS100 phase contrast 
microscope (Instruments Europe B.V. Amstelveen, The Netherlands). Images were captured every 
two to three days of every culturing condition. 
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3.7 Fixation and immunocytochemical staining 
 
The cultures were fixed and dyed according to our Heart Group’s double-fluorescence protocol 
(table 2). In brief, the cells were washed with PBS then fixed with 4 % PFA and blocked. After 
blocking and washing, a mixture of primaries Anti-Cardiac Troponin T (Abcam) and Vinculin 
(LifeTechnologies) or Vimentin (Abcam) was introduced. After an overnight incubation the cells 
were washed again and a mixture of secondaries (Alexa Fluor) was introduced and incubated for 
an hour. After multiple of washes samples were dried and mounted with DAPI containing 
vectashield (Vector) and stored light protected. The last two batches were dyed simultaneously, 
and the primaries were incubated only briefly. 
 
Table 2. The double-fluorescence protocol 
Step Reagents 
Wash 2 x 5 min PBS (0.01M, pH 7.4) 
Fixing 20 min 4% PFA 
Wash 2 x 5 min PBS (0.01M, pH 7.4) 
Blocking 45 min, room temperature 10% NDS (Biowest), 0.1% TritonX-100 (Sigma), 1% BSA 
(Sigma) in PBS 
Wash  1% NDS, 0.1% TritonX-100, 1% BSA in PBS 
Mixture of primaries, overnight +4°C 1. Troponin T (Abcam), origin: goat dilution 1:2000 OR 
2. Troponin T (Abcam), origin: mouse dilution 1:500 
1. Vinculin Ab (LifeTech.), origin: rabbit dilution 1:100 
OR 
2. Vimentin (Abcam), origin: goat dilution 1:300 
in 1% NDS, 0.1% TritonX-100, 1% BSA in PBS 
Wash 3 x 5-7 min 1% BSA (Sigma) in PBS  
Mixture of secondaries 1h, room temperature 1. Anti-goat 568(Alexa Fluor) origin: donkey dilution 
1:600 OR 
2. Anti-mouse 568 (Alexa Fluor) origin: donkey dilution 
1:600 
1. Anti-rabbit 488 (Alexa Fluor) origin: donkey dilution 
1:600 OR 
2. Anti-goat 488 (Alexa Fluor) origin: donkey dilution 
1:600 
Wash 3 x 5 min PBS (0.01M, pH 7.4) 
Wash 2 x 5 min PB 
Dry and mount + coverslips Vectashield mounting medium with DAPI (Vector) 
 
 
3.8 Fluorescence imaging 
 
The IX 51 Inverted Microscope (Olympus) was used for fluorescence imaging.  
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Individual cardiomyocytes were counted from these images and categorized by their nucleus 
count, uni- or multinucleated, in the following groups: all control samples and all co-cultures with 
6 %, 10 % and 20 % of MSCs. The statistical analysis of depencende was performed with SPSS 
release 23.0 (IBM Corp, Armonk, NY using the Pearson 2-test. Statistical significance was set to 
p<0.05. 
 
3.9 Quantitative polymerase chain reaction 
 
RNA was isolated from the samples and then converted into cDNA using High Capacity cDNA 
Reverse Transcription Kit (AppliedBiosystems, Thermo Fisher Scientific). 2 x RT Master Mix was 
prepared from the following reagents: 20 % 10 x RT Buffer, 8 % 25 x dNTP Mix (100mM), 20 % 10 x 
RT Random Primers, 10 % Multiscribe ReverseTranscriptase, 10 % RNase inhibitor and 32 % 
nuclease free H2O. In addition, a ReverseTranscriptase-free control mixture was prepared, and its 
volume was corrected with nuclease free H2O. RNA samples were mixed into 2 x RT Master Mix in 
a 1:2 ratio with a final volume of 20µl. Two 2 x RT Master Mix controls without RNA samples and 
two RT-free Master Mix controls were prepared. In total four 8-tube strips were created as 
illustrated in diagram 2. cDNA conversion was executed using Mastercycler Pro 5341’s (Eppendorf 
AG, Hamburg) thermal cycle program (table 3). 
 
8-tube strips 
D3%1 D3%2 D6%1 D6%2 D10%1 D10%2 D20%1 D20%2 
S3%1 S3%2 S6%1 S6%2 S10%1 S10%2 S20%1 S20%2 
DC1 DC2 SC1 SC EB1 EB2 MSC1 MSC2 
H2O1 H2O2 -RT + H2O -RT + EB     
Diagram 2. The converted cDNA samples. 
Code 
D: Plated as a droplet  MSC: MSC medium control 
S: Spread, plated in the medium H2O: 2 x RT Master Mix control, no sample 
C: MSCs’ conditioned medium -RT: RT-free Master Mix control without 
EB: Embryoid body medium control sample and with EB medium sample 
   %: the percentage of MSCs in the sample 
 
Table 3. Thermal cycle program used for cDNA conversion. 
 Step 1 Step 2 Step 3 Step 4 
Temperature 20°C 37°C 85°C 4°C 
Time 10min 120min 5min >>> 
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The cDNA concentration in each sample was 5ng per 10µl after 1:2 dilution assuming all of the 
RNA had converted. Four qPCR Master Mixes were prepared using the following reagents: for each 
reaction 5µl TaqMan Gene Expression Master Mix (AppliedBiosystems, Thermo Fisher Scientific), 
0,5µl 20xTaqMan Assays pool (GAPDH, TNNT2, Myh6 or Myh7) and 3,5µl nuclease free H2O. cDNA 
samples were added in a 1:10 ratio into two 96-well plates according to diagram 3. Each plate 
contained qPCR Master Mix with a different primer: GAPDH, TNNT2, Myh6 or Myh7. As to the last 
plate, only one droplet plated 3 % co-culture sample was created. 
 
D3%1 D6%1 D10%1 D20%1 S3%1 S6%1 S10%1 S20%1 DC1 SC1 EB1 MSC1 
D3%1 D6%1 D10%1 D20%1 S3%1 S6%1 S10%1 S20%1 DC1 SC1 EB1 MSC1 
D3%1 D6%1 D10%1 D20%1 S3%1 S6%1 S10%1 S20%1 DC1 SC1 EB1 MSC1 
D3%2 D6%2 D10%2 D20%2 S3%2 S6%2 S10%2 S20%2 DC2 SC2 EB2 MSC2 
D3%2 D6%2 D10%2 D20%2 S3%2 S6%2 S10%2 S20%2 DC2 SC2 EB2 MSC2 
D3%2 D6%2 D10%2 D20%2 S3%2 S6%2 S10%2 S20%2 DC2 SC2 EB2 MSC2 
      -RT1 -RT1 -RT1 H201 H201 H201 
      -RT2 -RT2 -RT2 H202 H202 H202 
Diagram 3. Samples for qPCR. Four comparable plates with a different primer were created.  
Primers used were TNNT2, GAPDH, MYH6 and MYH7. 
The quantitative PCR was carried out in 7300 Real Time PCR System (AppliedBiosystems) as shown 
in table 4. 
   Table 4. qPCR program. 
Temperature time cycles 
50°C 
95°C 
2min 
10min 
1 
95°C 
60°C 
15s 
1min 
40 
 
To evaluate relative quantification the 2-Ct method was used (40). GAPDH was set as the internal 
control gene and MSC medium control was chosen as the calibrator. The fold change of the target 
genes TNNT2, MYH6 and MYH7 was evaluated in the EB medium control, conditioned medium and 
co-cultures with 6 % and 10 % of MSCs. The number of samples was 6 for the MSC and EB medium 
controls and 12 for the conditioned medium and co-cultures. Each culturing condition was 
compared with the MSC medium control. The statistical analysis of the differences was conducted 
using Kruskal-Wallis test for independent samples in SPSS release 23.0 (IBM Corp, Armonk, NY). 
Statistical significance was set to p < 0.05. 
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4. RESULTS 
4.1 Microscopy and culture appearance 
 
Panel 1 shows the difference between the used plating strategies as well as the test and control 
cultures at the beginning and end of culturing. Samples in which hiPSC-cardiomyocytes were 
plated onto the gel in a droplet will be referred as the “droplet group” as the samples in which 
hiPSC-CMs were plated directly into the culturing medium will be referred as the “spread group”.  
 
As seen in panel 1, the cultures were already dense in the droplet group while being sparse in the 
spread group during day 1 or 2 of culturing. Individual hiPSC-CMs are clearly visible throughout the 
spread cultures and within the edges of the cell clusters in the droplet group. Panel 1 also shows 
that the cultures grew in in all culturing conditions in the droplet group. Co-cultures with 10 % and 
20 % of hMSCs were most dense. In the spread group the EB controls and conditioned cultures 
were still sparse at this point. Co-cultures became increasingly full complying with the ratio of 
hMSCs. 
 
hMSCs appeared in all co-cultures and were detected increasingly according to their plated ratio 
(Panel 1). At the beginning of the co-culturing individual hMSCs were observed amidst the hiPSC-
CMs but most of them appeared within the margins of the cultures (image 1) in the droplet group, 
whereas hMSCs situated randomly amongst the hiPSC-CMs (panel 1) in the spread group. 
Proliferation of the hMSCs was rapid and more evident in spread group (image 3). As the cultures 
grew in it became difficult to distinguish the cell types. hMSCs seemed to adhere to one another 
with long projections (image 2). Only hiPSC-CMs were present in the conditioned samples and 
controls apart from the MSC-medium control in the spread group which was full of fibroblast-like 
cells at the end of the trial.  
 
It becomes evident from panel 1 that the hiPSC-CMs appeared similar in the test and control 
samples throughout culturing. Beating cells were detected in all culturing conditions but weren’t 
analyzable. In the droplet group, hiPSC-CMs were mainly round or cubic in shape in all culturing 
conditions in the beginning of the trial whereas multiple elongated hiPSC-CMs appeared in the 
spread group. By the end of the culturing, most of the hiPSC-CMs in the spread group appeared 
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also round or cubic in shape. Lace-like structuring or intracellular vesicles of the hiPSC-CMs 
appeared after culturing in all culturing conditions. In panel 1 this can be seen best in the droplet 
group co-culture with 10 % of hMSCs at day 7. Enlarged hiPSC-CMs (image 4) were present in 
areas sparse with cells, that is in the spread cultures and within the edges in the droplet group.
 
Panel 1. Light microscope images captured during two weeks of culturing. Spread and droplet plated hiPSC-CMs are 
presented separately. Wells with droplet plated hiPSC-CMs are already dense at the beginning of culturing whereas individual 
hiPSC-CMs are abundant in “the spread group” even by the end of culturing. hMSCs appear in all co-cultures and increase 
according to their plated ratio. hMSCs are easier to detect amidst the hiPSC-CMs and seem to expand more rapidly in “the spread 
group”. Multiple elongated hiPSC-CMs are seen in “the spread group” at the beginning but not at the end of culturing.  
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Image 1. hMSCs in the margins of the well.                          Image 2. Projections between adjacent hMSCs. 
  
Image 3. Multiple hMSCs in spread 6% MSC co-culture.     Image 4. Enlarged hiPSC-CMs. 
 
4.2 Fluorescence images 
 
As seen in panel 4, the appearance of the hiPSC-cardiomyocytes seems similar throughout all 
culturing conditions and is mainly round or cubic despite the plating strategy or the test setup. Few 
cells with sarcomeres and ladder structures are detected by eye but no culturing condition seems to 
exhibit this more than others.  
 
In general, cultures in the droplet group and the spread co-cultures and are highly abundant with 
cells as the EB-control and conditioned medium cultures in the spread group are relatively sparse 
(Panel 4). Cultures with hiPSC-CMs plated in a droplet created hiPSC-CMs clusters whereas there 
were few adjacent hiPSC-CMs in the spread group (Panel 2). Only hiPSC-CMs are present in the 
control and conditioned medium cultures, except for the MSC-medium control of the second trial in 
which fibroblast-like cells are abundant in all samples (Panel 4).  
 
Vimentin or vinculin stained cells (green), presumably hMSCs, can be found in all co-cultures. These 
cells seem increasingly abundant in higher hMSC concentrations as expected. All the samples, 
droplet or spread, with 20 % of hMSCs are packed with these cells. The count of hMSCs seems to 
increase when the hiPSC-CMs are scattered, that is, in the spread group and in the margins of the 
droplet cultures (Panel 2 and 3). hMSCs seem to mainly surround the hiPSC-CMs when the hiPSC-
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CMs are clustered. However, hMSCs begin to overlap cardiomyocytes in high hMSC concentrations 
and when the hiPSC-CMs are more scattered (Panel 2 and 3). 
 
As seen in diagram 4, the nucleus count did not depend on the presence of hMSCs, 2 (3, N = 381), = 
3,538, p = 0,316). The ratio of multinucleated cells was highest (24 %) in the control group and in 
the co-culture with 10 % of hMSCs (22 %). Co-culture with 6 % of hMSCs had the lowest count of 
multinucleated cells (14%).  
 
Table 5. The number and portion of uni- and polynucleated cells in different culturing conditions. There was no significant 
difference in the amount of polynucleated hiPSC-CMs between the groups. 
 Cell count (CMs) Portion 
Culturing 
condition Uninucleated Polynucleated Total 
Uninucleated Polynucleated 
Controls 79 25 104 0,75961538 0,24038462 
6% MSCs 76 12 88 0,86363636 0,13636364 
10% MSCs 65 18 83 0,78313253 0,21686747 
20 % MSCs 86 20 106 0,81132075 0,18867925 
 
 
Diagram 4. Cell distribution according to the nucleus count.  
hMSCs did not affect the number of polynycleated hiPSC-CMs 
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
1.1
Controls 6% MSCs 10% MSCs 20 % MSCs
Uninucleated Polynucleated
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Panel 2. Coverage of the wells and cell distribution in the “droplet group” compared to the “spread group”. hiPSC-CMs plated 
in a droplet created cell clusters as there are fewer adjacent cells in the “spread group”. hMSCs are more abundant in the spread 
group and intrude the space between hiPSC-CMs. hMSCs overlap hiPSC-CMs in higher concentrations (20 % MSCSs, droplet). 
 
Panel 3 hMSCs in the well margins. hMSCs are highly abundant in areas sparse with hiPSC-CMs and being to overlap these cells. 
  24 
 
Panel 4. General appearance of the cultures. hiPSC-CMs appear similar in all cultures. Cultures are dense in the  
”droplet group” and co-cultures in the “spread group”. Fibroblast-like cells are present in the spread MSC medium control. 
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4.3 qPCR data 
 
The relative expression of TNNT2, MYH6 and MYH7 was highest in the EB medium compared to 
the co-cultures which had the lowest overall cardiac specific gene expression (Diagram 5A-C). 
Similar results were obtained within the MYH7/MYH6-ratio alongside with EB medium outdoing 
the MSC medium (Diagram 5D). Compared to the 10 % MSC co-culture, TNNT2 and MYH6 was 
elevated in MSC medium and TNNT2 in conditioned samples (Diagram 5A&B).  
 
 
 
Diagram 5. Quantitative PCR results with MSC medium control as the calibrator. MSC medium and EB controls (n = 6), Conditioned, 
6 % MSCs and 10 % MSCs (n = 12). Error bars display the standard error of the mean (SEM). A) p = 0,001 in EB vs. 10 % and 6 %, p = 
0,01 in MSC vs. 10 % and Cond vs. 10 %. B) p < 0,01 in EB vs. 10 % and EB vs. 6 %, p < 0,05 in MSC vs. 10 %. C) p < 0,001 in EB vs. 10 % 
and 6 %. D) p < 0,001 in EB vs. 10%, p = 0,01 in EB vs. 6% and EB vs. MSC. Other differences were statistically non-significant.  
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5. DISCUSSION 
 
 
These results show that human iPSC-CMs can be successfully co-cultured with human MSCs. This 
study also suggests that the hMSCs had no hazardous impact on the iPSC-CMs although they 
proliferate faster during culturing and should therefore be plated in lesser extent than the hiPSC-
CMs. However, there was no evidence of any beneficial effects the hMSCs might have on the 
maturation or survival of the cardiomyocytes. 
 
It was unclear whether the same culturing medium was suitable for both hiPSC-CMs and hMSCs. 
Various protocols exist in culturing of the adipose tissue derived MSCs. These protocols usually 
involve a DMEM based medium with 10 % FBS but its eligibility for the hiPSC-CMs and co-culturing 
purposes was uncertain (41,42). Differentiation medium for the hiPS-CMs on the other hand is 
typically composed of a DMEM-F12 basal medium with 20 % FBS although other basal mediums 
such as KO-DMEM can also be applied (43). Increase in the presence of FBS can enhance the MSCs’ 
proliferation rate but is more likely to depend on the overall amount of growth inducing 
supplements (42). Solutions with less than 5 % FBS have also shown to reduce the size of the 
hiPSC-CMs (44). The visual assessment indicated that the MSC-medium was suitable for the hiPSC-
CMs and co-culturing as the hiPSC-CMs appeared similar in all cultures. However, the expression 
of cardiac markers was higher in the EB-medium which suggests its superior performance. 
Although being an essential tool in cell differentiation and culture survival, animal originating 
serum is a problematic supplement for it rules out in vivo purposes and its content varies due to 
poor reproducibility (45). 
 
Based on our findings hiPSC-CMs survival was increased when plated in a droplet. However, some 
analyzing methods require solitary cardiomyocytes which were more abundant in the spread 
group (44). The hMSCs had a high proliferation rate which was most evident when the hiPSC-CMs 
were sparse. A possible explanation for this is the lack of free surface limiting the hMSCs’ 
proliferation and migration. The hMSCs also began to overlap with the hiPSC-CMs in the higher 
hMSC/hiPSC-CM-ratios and was present even within dense hiPSC-CM clusters in the highest 
hMSCs concentrations. This might implicate to a competitive situation. It can therefore be 
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concluded that the droplet group tolerates a higher hMSC concentration than the spread group. 
The less restricted propagation of the hMCSs in the latter group could also further limit the hiPSC-
CMs cell-to-cell contacts but would on the other hand increase the likelihood of hMSC-hiPSC-CM 
cell-to-cell contacts. The projections observed between the MSCs likely refer to cell-to-cell 
interactions. Lastly, due to their proliferation capacity the concentration of the hMSCs should be 
kept at the minimum in order to restrain the overpopulation of the cultures. 
 
Despite some variation in the shape and size of the cells only few cells displayed an elongated 
morphology. Contrary to our findings, Yoshida’s group which shared a similar research design with 
our study, reported a significant decrease in cell sphericity in their co-cultures (p < 0.001) but the 
reported number of cells used for this analysis was only seven (27). The co-culturing neither 
increased multinucleated cells in the analyzed groups which also speaks against improved 
maturation. The individual hiPSC-CMs seemed to expand in low hiPSC-CM-densities which is in line 
with previous studies (46). The cause of the blistering phenomenon of the hiPSC-CMs in the 
microscope images remains unknown but is unlikely caused by the hMSCs as it also occurred in 
both controls. We hypothesized this phenomenon could implicate cell stress or even apoptotic 
blebs but these hiPSC-CMs were clearly beating which conflicts with this theory. 
 
It should be noted that the presence of MSCs in co-cultures increase the amount of GAPDH which 
can distort qPCR results when used as the internal control. Therefore, this could partially explain 
the EB medium’s superior cardiac specific gene expression. However, this medium appeared to 
perform better compared to MSC medium although the difference was statistically non-significant. 
Moreover, the MYH7/MYH6-ratio which does not rely on GAPDH was also compatible with these 
results. Yoshida et al. excluded the direct co-cultures from their qPCR analysis and discovered an 
increase in the mRNA expression of a cardiac maturation marker myosin heavy chain 7 (p = 
0.0272) in the conditioned samples whereas the expression of myosin heavy chain 6 did not differ 
significantly (27). This finding was supported by western blotting analysis which revealed an 
increase in the myosin heavy chain- (MHC-) to MHC- ratio in this group (p = 0.0455) (27). 
Although our results did not agree with these findings, they could be affected by the less suitable 
culturing medium.  
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Our study’s advantage was the long 14-day culturing period compared to Yoshida’s group’s 3-day 
culturing providing a better outlook on the long-term impacts of the co-culturing process. Their 
short culturing period could further explain the use of relatively high concentrations of the hMSCs 
being 25 % and 50 % in the indirect and 1:1 in the direct co-cultures. Our study showed that even 
hMSC concentrations of 3 % expanded significantly during the two-week culturing. Contrary to our 
study Yoshida et al. utilized a semipermeable membare instead of pre-conditioned medium. (27) 
 
Other previous studies on co-culturing MSCs with cardiomyocytes focus mainly on the MSCs’ 
ability to differentiate into cardiomyocytes (31,32,47). Studies involving rat cardiomyocytes and 
rat MSCs or human adMSCs demonstrated cardiac marker expression such as -actin, cTnT and 
cardiac myosin heavy chain by the MSCs in direct co-culture with cardiomyocytes (31,32). Similar 
results were obtained when human MSCs were in direct co-culture with human cardiomyocytes 
(47). These hMSCs in direct co-culture with hCMs expressed MYH7, -actinin, troponin-I and 
troponin-T while only -actinin was expressed in conditioned medium treated samples (47). 
Additionally Choi YS et al. discovered beating adMSCs with gap junctions with adjacent 
cardiomyocytes (32).  
 
Study limitations 
 
A major challenge in this study was the differentiation of the two cell types when analyzing the 
data. The presence of hMSCs in the co-cultures prevented the reliable use of GAPDH as a 
reference gene. It would have also been impossible to identify the cause of possible marker gene 
expression variations solely by qPCR considering the hypothesis of hiPSC-CMs maturation and 
hMSC differentiation. Although the hMSC pre-conditioned medium samples suited this analysis, 
the preservation and therefore the potency of this medium was questionable. Fluorescence 
images would have enabled computerized cell-shape analysis but was ruled out due to inadequate 
number of individual cells. In addition, user-based selection in the imaging process exposes to 
inherent bias.  
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Conclusions 
 
Both culturing mediums used were suitable for culturing of hiPSC-CMs and co-cultures although EB 
medium performed better with the hiPSC-CMs. Nonetheless, FBS-free alternatives should be 
discovered. The plating strategy affects the distribution of the hiPSC-CMs and should therefore be 
considered while selecting the analyzing methods (48). Additionally, hMSCs proliferate more 
efficiently in sparse hiPSC-CM cultures and thus require lower hMSC quantities. Eligible analyzing 
methods for evaluating direct co-cultures should be explored. There was no indication that the 
hMSCs would affect the hiPSC-CMs’ maturation but further studies on this topic are still required.  
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Stock solutions used 
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Dulbecco’s Modified Eagle Medium/Nurtient Mixture F-12 (DMEM/F-12), Gibco 
ThermoFischer Scientific 
KnockOut D-MEM (KO-DMEM), Gibco ThermoFischer Scientific 
mTeSR™1, components: mTeSR1 Basal Medium and mTsR1 5X Supplement (StemCell 
Technologies) 
Phosphate-buffered saline (PBS), Gibco ThermoFischer Scientific 
Phosphate-buffer (PB) 
Bovine serum albumin (BSA), Sigma 
Donkey serum (NDS), Biowest 
PFA (paraformaldehyde) 
Abbreviations 
bFGF basic fibroblast growth factor 
TGF transforming growth factor beta 
BMP4 bone morphogenic protein 4 
IWP-4 inhibits Wnt signaling 
KLF4 Kruppel-like factor 4 
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